US Markets for Neurostimulation Products
This article was originally published in Start Up
Executive Summary
According to "US Markets for Neurostimulation Products," a report published in November 2006 by the Medtech Insight division of Windhover Information Inc., neurostimulation devices have the potential to address several clinical applications in which patient populations number in the millions: chronic pain affects five million people in the US; chronic depression four million, and chronic migraine headache two million. Based on projects currently in development, Medtech Insight lists 18 separate clinical indications for neurostimulation, from Alzheimer's disease to sleep apnea.
You may also be interested in...
Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.
Seizure Desist: Neurostim Companies Pursue Alternative Treatments for Epilepsy
The rise of interest in neurostimulation and neuromodulation approaches is leading venture capitalists and large medical device companies to develop devices to prevent or block seizures. The devices would be used primarily on patients who don't respond to drugs for epilepsy.
Business & Technology Briefs (03/2007)
Brief summaries of recent product and clinical developments in the device industry, including developments in Cardiac and Peripheral Devices, Miniature Robotic Devices, and Diabetes Management.